In Re: Celexa and Lexapro Marketing and Sales Practice Litigation-A Harbinger of Change in the Prescription Drug Preemption Landscape

Bloomberg BNA's Pharmaceutical Law & Industry Report
March 24, 2015

In a decision that seems to have generated less discussion than it deserves, the First Circuit Court of Appeals may have significantly altered the litigation landscape for preemption of state law actions that challenge branded (NDA) drug labels. Click here to read the full article.

(Reproduced with permission from Pharmaceutical Law & Industry Report, 13 PLIR 446, 03/27/2015. Copyright © 2015 by The Bureau of National Affairs, Inc. (800-372-1033)

Practice Areas

Jump to top of page

By using this site, you agree to our updated Privacy PolicyTerms & Conditions, and Cookies Policy.